SalivaOptimize™ Proteinase K [20mg/ml]
FDA has recently approved under EUA (Emergency Use Authorization) the use of SalivaDirect Assay 1,2 for SARS-CoV-2 detection. The SalivaDirect assay is simple, rapid and does not require any lengthy procedure of RNA extraction. In addition, the assay utilizes saliva samples instead of nasopharyngeal swabs which are uncomfortable to the sample provider and coughing while collecting nasopharyngeal swab increase the chances of nosocomial spread of virus.
In SalivaDirect assay, the saliva sample is collected from the sample provider and treated with proteinase K to digest enzymes and proteins. This is followed by inactivation of Proteinase K by heating the sample at 95°C. The saliva sample treated with proteinase K is directly used for RT-qPCR for Covid 19 detection2. Furthermore, the sensitivity of the assay has been found to be more than nasopharyngeal swabs and viral nucleic acid extraction2.
G-Biosciences SalivaOptimize™ Proteinase K has been optimized to provide maximum proteolytic activity within a short period for rapid and maximum release of Covid-19 viral nucleic acid for RT-qPCR detection technique.
Specifications
Form: liquid
Activity: ≥ 30 U/mg
Specific Activity: ≥ 40 U/mg protein
Purity: DNAse and RNase free (Molecular grade)
Application(s)
- Optimized to provide maximum proteolytic activity within a short period for rapid and maximum release of Covid-19 viral nucleic acid for RT-qPCR detection technique.
- Suitable for other nucleic acid extraction protocols
References:
- https://www.fda.gov/media/141192/download
- Wyllie A. L., et al (2020). Saliva is more sensitive for SARS-Cov-2 detection in covid -19 patients than nasopharyngeal swabs. MedRxiv. https://doi.org/10.1101/2020.04.16.20067835doi.